Cytokinetics, Inc. (CYTK) Posts Q1 Loss of 27c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Cytokinetics, Inc. (CYTK) Posts Q1 Loss of 27c/Share
May 7, 2014 9:29 AM EDT
Roth Capital has Cytokinetics (Nasdaq: CYTK) at Buy with a target price of $13 following Q1 results.
After markets closed Tuesday, Cytokinetics reported Q1 EPS of ($0.27), $0.07 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $8 million versus the consensus estimate of $7.69 million.
Analyst Joseph Pnatginis noted that Cytokinetics is now prepping for the potential next steps for tirasemtiv... More
May 7, 2014 8:41 AM EDT
Needham & Company analyst Chad Messer reiterated a Buy rating and $15 price target on Cytokinetics (NASDAQ: CYTK) following Q1 results.
Messer comments, "Cytokinetics ended 1Q:14 with $101.9 million in cash, which we estimate is sufficient to fund the company at least through 2015. On its earnings... More
